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Introduction
Wegener’s granulomatosis (WG) is an autoimmune
disease of unknown etiology characterized by granuloma-
tous and vasculitic lesions. Localized WG, in which granu-
lomatous lesions are restricted to the respiratory tract,
may precede ‘classical’ generalized WG. Observation of a
disease course of localized WG without progression for
several years has remained a rare finding [1]. The disease
usually progresses to generalized WG, in which clinical
manifestations of frank autoimmune vasculitis prevail, for
example pulmonary–renal syndrome. An autoantibody,
namely antineutrophil cytoplasmic antibody specific for
proteinase 3 (PR3-ANCA), is detected in the vast majority
of patients with generalized WG [1,2]. Whereas granulo-
matous lesions express predominantly T helper type 1
(Th1)-type cytokines in localized WG [3], a shift towards
stronger Th2-type cytokine expression is found in granulo-
matous lesions of the respiratory tract in generalized WG
ANCA = antineutrophil cytoplasmic antibody; APC = allophycocyanine; BVAS = Birmingham Vasculitis Activity Score; CD45RA = long human
isoform of CD45; CD45RO = short human isoform of CD45; CD62L = L-selectin; CCR3 = CC chemokine receptor 3; CCR5 = CC chemokine
receptor 5; CXCR3 = CXC chemokine receptor 3; DEI = Disease Extent Index; FITC = fluorescein isothiocyanate; HC = healthy controls; PBMC =
peripheral blood mononuclear cells; PE = phycoerythrin; PerCP = peridinin chlorophyll protein; PR3 = proteinase 3; Th1 = T helper type 1; WG =
Wegener’s granulomatosis.
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Abstract
Memory T cells display phenotypic heterogeneity. Surface
antigens previously regarded as exclusive markers of naive
T cells, such as L-selectin (CD62L), can also be detected on
some memory T cells. Moreover, a fraction of CD45RO+
(positive for the short human isoform of CD45) memory T cells
reverts to the CD45RA+ (positive for the long human isoform of
CD45) phenotype. We analyzed patients with biopsy-proven
localized Wegener’s granulomatosis (WG) (n = 5), generalized
WG (n = 16) and age- and sex-matched healthy controls
(n = 13) to further characterize memory T cells in WG. The cell-
surface expression of CD45RO, CD45RA, CD62L, CCR3,
CCR5 and CXCR3 was determined on blood-derived T cells
by four-color flow cytometric analysis. The fractions of CCR5+
and CCR3+ cells within the CD4+CD45RO+ and
CD8+CD45RO+ memory T cell populations were significantly
expanded in localized and generalized WG. The mean
percentage of Th1-type CCR5 expression was higher in
localized WG. Upregulated CCR5 and CCR3 expression
could also be detected on a fraction of CD45RA+ T cells.
CD62L expression was seen on approximately half of the
memory T cell populations expressing chemokine receptors.
This study demonstrates for the first time that expression of the
inducible inflammatory chemokine receptors CCR5 and CCR3
on CD45RO+ memory T cells, as well as on CD45RA+ T cells
(‘revertants’), contributes to phenotypic heterogeneity in an
autoimmune disease, namely WG. Upregulated CCR5 and
CCR3 expression suggests that the cells belong to the effector
memory T cell population. CCR5 and CCR3 expression on
CD4+ and CD8+ memory T cells indicates a potential to
respond to chemotactic gradients and might be important in T
cell migration contributing to granuloma formation and
vasculitis in WG.
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[3,4]. In kidney lesions of generalized WG, the expression
of both Th1-type and Th2-type cytokine and chemokine
receptors has been described. Thus, the local cytokine
milieu might depend on the site and extent of disease
activity [4,5]. The shift in the cytokine profile in granuloma-
tous lesions of the respiratory tract might be of importance
for disease progression [2,3].
The term effector memory T cells has been used to denote
memory T cells that display migratory properties, readily
produce cytokines and release granular contents [6–8].
These cells show striking tissue selectivity of migration
and are preferentially recruited to sites of inflammation
[7,8]. The phenotype of memory T cells is heterogeneous.
A fraction of CD45RO+ (positive for the short human
isoform of CD45) memory T cells reverts to the phenotype
CD45RA+ (positive for the long human isoform of CD45)
[9]. Antigen-experienced T cells, for example virus-specific
T cells, were found to display considerable heterogeneity
with regard to their CD45 isoform expression [10,11].
Surface antigens formerly regarded as exclusive markers
of naive T cells, such as L-selectin (CD62L) or the CC
chemokine receptor CCR7, were also found to be
expressed on a fraction of memory T cells including tissue-
specific cells [10,12]. Thus, distinction between naive and
memory T cells cannot be based on the analysis of single
surface antigens. A combination of surface markers and
the function of the T cell have to be considered in distin-
guishing naive from memory T cells [9–12].
In granulomatous lesions, CD4+ and CD8+ T cells express
the CD45RO isoform consistent with a memory pheno-
type [13]. However, the intralesional expression of
CD45RA isoforms has yet not been analyzed. RANTES
(‘regulated upon activation in normal T cells, expressed
and secreted’; also known as CCL5), a ligand for the CC-
chemokine receptors CCR1, CCR3 and CCR5, has
recently been demonstrated in pulmonary granulomatous
lesions in WG. The chemokine is expressed mainly in
macrophages and may promote the recruitment of effector
memory T cells into the lesion [13].
In the present study we analyzed CCR5 and CCR3
expression on T cells to determine the surface antigens
important for the recruitment of cells, namely the exertion
of migratory functions and a prerequisite for the formation
of granulomatous lesions and vasculitis in WG. Because
chemokine receptors such as the inducible inflammatory
chemokine receptors CCR5 and CCR3 – along with
selectins and adhesion molecules – have a pivotal role in
effector memory T cell trafficking into inflammatory areas
[6–8], we proposed that CCR5 or CCR3 is expressed on
CD4+ and CD8+ effector memory T cells. We further pro-
posed that differences in the chemokine receptor expres-
sion might contribute to the recruitment of distinct effector
memory T cell populations into granulomatous lesions,
resulting in different cytokine patterns within granuloma-
tous lesions in localized WG and generalized WG. This in
turn might also influence the outcome of the disease
course (localized versus generalized WG). Moreover, the
analysis of relevant chemokine receptor expression unrav-
els new targets for a specific therapy directed against
chemokine receptors.
Materials and methods
Study population
Peripheral blood mononuclear cells (PBMC) from 5
patients with localized WG, 16 patients with generalized
WG, and 13 age- and sex-matched healthy controls (HC)
were analyzed. All patients met the criteria of the American
College of Rheumatology [14] and the Chapel Hill Con-
sensus Conference definition for WG [15]. WG was
biopsy-proven in each patient. Biopsies were seen in a
German reference center for vasculitis (Department of
Pathology, University of Lübeck) by two independent
observers (KHU and ACF). All patient charts of patients
with localized and generalized WG were critically evalu-
ated by an interdisciplinary group [1].
Subclassification of WG into localized and generalized
WG was done in accordance with the definitions given for
both disease stages by the European Vasculitis Study
Group [16]. PR3-ANCA was detected in all patients with
generalized WG. Disease extension and vasculitis activity
were documented by using the Disease Extent Index (DEI)
and the Birmingham Vasculitis Activity Score (BVAS) as
outlined elsewhere [17,18]. In brief, the DEI gives the
equivalent of organ involvement attributable to active
disease in WG [17], whereas the BVAS considers clinical
features and laboratory data to give a measure of vasculi-
tis activity [18]. In its current version BVAS.1 represents a
score of new or worse disease activity, namely active
disease, whereas BVAS.2 represents a score of disease
activity due to persisting disease [18].
There were two groups of patients with generalized WG:
nine patients with generalized WG had active disease
(BVAS.1 ≥ 4, DEI ≥ 2), whereas seven patients were in
remission (BVAS.1 = 0, BVAS.2 ≤ 3), i.e. evidence of partial
or complete improvement of vasculitis activity by clinical and
serological investigations and by imaging procedures. All
patients with localized WG were in remission, with some
symptoms still persisting because of the damage caused by
preceding active disease. Treatment consisted of cortico-
steroids (1 patient with localized WG and 14 patients with
generalized WG), cyclophosphamide (0/5), methotrexate
(1/9), azathioprine (0/2), leflunomide (0/3, in combination
with methotrexate) and cotrimoxazole (3/0).
Antibodies and reagents
The following antibodies were used for flow cytometric
analysis of cells: CD4–APC (APC = allophycocyanine),R27
CD8–APC, CD45RO–PE (PE = phycoerythrin),
CD45RA–FITC (FITC = fluorescein isothiocyanate),
CD45–PerCP (PerCP = peridinin chlorophyll protein),
CD62L–PerCP (BD, Heidelberg, Germany), CCR5–PE,
CCR5–FITC, CCR3–PE, CCR3–FITC, CXC chemokine
receptor 3 coupled to FITC (CXCR3–FITC), and RANTES
(R&D, Wiesbaden, Germany). Isotype control antibodies
were as follows: Rat IgG2a–FITC, mouse IgG2a–FITC,
mouse IgG2a–PE, mouse IgG2b–FITC, mouse
IgG2b–PE, mouse IgG1–FITC and mouse IgG1–PE (BD,
Heidelberg, Germany). To test the specificity of the anti-
bodies, PBMC were incubated for 30 minutes with
increasing concentrations of RANTES (1–1000 ng/ml;
R&D, Wiesbaden, Germany). After a washing step, stain-
ing for CD4, CD45RO and CCR5 was performed. At the
highest RANTES concentration, CCR5 staining was
almost completely blocked.
Cell-surface marker staining and flow cytometry
PBMC were isolated by Ficoll–Hypaque density-gradient
centrifugation. Cells were resuspended in buffer contain-
ing 0.1% bovine serum albumin and 0.1% NaN3 at
106 cells/ml. Nonspecific antibody binding at the Fc
receptor was blocked by treating 106 cells with 10 µg
human IgG (Chromopure) for 15 minutes at room temper-
ature. Afterwards 105 cells were stained in 100 µl of
buffer containing the previously determined optimal con-
centrations (0.25–1.0 µg/100 µl) of fluorochrome-conju-
gated monoclonal antibodies for cell surface antigens or
appropriate negative (isotype) controls. Incubation was
performed at 4°C for 30 minutes in the dark. After a
washing step, cells were fixed with 300 µl of PBS contain-
ing 1.5% paraformaldehyde. Four-color flow cytometric
analysis by fluorescence-activated cell sorting was per-
formed with a FACSCalibur™ flow cytometer (BD, Heidel-
berg, Germany). Data were acquired with CELL-Quest™
software (BD, Heidelberg, Germany). CD4+ or CD8+ lym-
phocytes were gated for analysis based on light scattering
properties and on CD4 or CD8 and CD45 staining. Data
were collected for 104 lymphocytes. Positively and nega-
tively stained populations were calculated by quadrant dot
plot analysis determined by isotype controls.
Statistical analysis
A non-normal distribution was assumed and a nonpara-
metric test (Mann–Whitney test) was performed. P < 0.05
was regarded as significant.
Results
CD45RA+ and CD45RO+ T cells express CCR3, CCR5 and
CXCR3
The median CD4+/CD8+ T cell ratio was 2.5 (range
1.1–4.4) in localized WG, and 1.1 (0.6–2.6) in general-
ized WG, whereas it was 1.7 (0.9–7.1) in HC. There
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Figure 1
Representative flow-cytometric analysis of cell-surface chemokine receptor expression on CD4+ T cells. Peripheral blood mononuclear cells from a
patient with localized Wegener’s granulomatosis (WG), from a patient with generalized WG and from a healthy control were simultaneously stained
with CD4–APC, CD45RO–PE, CD45–PerCP, and either CCR5-FITC or CCR3-FITC. CD4-positive lymphocytes were gated on the basis of light-
scattering properties and on CD4 and CD45 staining, then analyzed for expression of CD45RO and CCR5 or CCR3.were no differences between the absolute leukocyte and
lymphocyte counts in localized WG, generalized WG and
HC. HC displayed low-level cell-surface expression of
CCR5 and CCR3, which might be in response to some
antigenic challenge. CCR5 and CCR3 expression was
significantly upregulated on CD4+ and (even more
strongly) on CD8+ T cells in both localized and general-
ized WG compared with HC (Figs 1 and 2). Chemokine
receptor expression was not confined to the CD45RO+
population: CD45RA+ T cells also had upregulated
CCR5 and CCR3 expression. In localized WG, CCR5
expression was generally significantly higher than CCR3
expression. In generalized WG, CCR3 expression was
similar to CCR5 expression. Co-expression of CXCR3
was detected on up to one-quarter of CCR5+ T cells
within either the CD45RO+ or the CD45RA+ T cell popu-
lation.
We found no significant differences in the mean percent-
ages of CCR5 expression and CCR3 expression on the
CD4+ and CD8+ memory T cell subsets between active
generalized WG and generalized WG in remission. The
corticosteroid dose was significantly higher in generalized
WG, both active and in remission (10.9 ± 2.0,
0–25 mg/day orally; mean ± SEM, range), compared with
localized WG (0.8 ± 0.8, 0–4 mg/day p.o.; P < 0.01).
CD62L expression on chemokine receptor expressing
CD45RA+ and CD45RO+ T cell populations
To address the question of whether CD62L expression is
confined to naive T cells or is also seen on some memory
T cells in WG, we analyzed CD62L expression on T cells
expressing chemokine receptors. Approximately half of the
CD4+CD45RO+, CD8+CD45RO+, CD4+CD45RA+ and
CD8+CD45RA+ T cell populations expressing CCR5 or
CCR3 were also expressing CD62L. Thus, some memory
T cells might also express CD62L in WG. In contrast,
mean CD62L expression was significantly higher on
CD4+CD45RA+ and CD8+CD45RA+ T cells not express-
ing CCR5 or CCR3 (89.2 ± 3.1, range 80.6–96.4% and
66.0 ± 13.0, range 21.4–93.0%; P < 0.05). Thus, most
CD45RA+ T cells not bearing CCR5 or CCR3 have to be
regarded as naive T cells expressing CD62L for their
homing to secondary lymphoid tissues [5–7].
Discussion
In WG, molecules involved in the recruitment of T cells
into granulomatous lesions are E- and P-selectin and
Arthritis Research and Therapy    Vol 5 No 1 Lamprecht et al.
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Figure 2
Cell-surface expression of the chemokine receptors CCR5 and CCR3 on T cells in localized Wegener’s granulomatosis (lWG), generalized WG
(gWG) and healthy controls (HC). Bars represent the fractions (given as percentages, means ± SEM) of either CCR5+ or CCR3+ cells within the
CD4+CD45RO+, CD4+CD45RA+, CD8+CD45RO+ and CD8+CD45RA+ T cell populations.ICAM-1 expressed on the endothelial side, and the β2-
integrin LFA-1 on T cells [5,19]. In addition to the steps
mediated by selectin and adhesion molecules, chemokine
receptors support the selective recruitment of differenti-
ated T cells into tissues through interaction with endothe-
lial and tissue-expressed chemokines [6–8]. In the present
study we analyzed the expression of the inducible inflam-
matory chemokine receptors CCR5 and CCR3 on CD4+
and CD8+ memory T cells, important for their recruitment
to inflammatory sites, in other words the exertion of migra-
tory effector functions, in WG. We found the expression of
the chemokine receptors CCR5 and CCR3 to be signifi-
cantly upregulated on peripheral blood CD4+ and CD8+ T
cells in localized and generalized WG. Predominance of
CCR5 expression over CCR3 expression was detected in
localized WG but not in generalized WG. Moreover, this
pattern of chemokine receptor expression was detected
similarly on CD4+CD45RO+, CD4+CD45RA+,
CD8+CD45RO+ and CD8+CD45RA+ T cells. CD62L
expression was also seen on approximately half of the
aforementioned T cell populations expressing chemokine
receptors, whereas CD4+CD45RA+ and CD8+CD45RA+
T cells not expressing CCR5 or CCR3 displayed a signifi-
cantly higher expression of CD62L.
Upregulated CCR5 and CCR3 expression on
CD4+CD45RO+ and CD8+CD45RO+ and also on
CD4+CD45RA+ and CD8+CD45RA+ T cells indicates
activation and the potential to respond to chemotactic gra-
dients in inflammatory areas, which is consistent with an
effector memory T cell phenotype [6–8].
Because it remains an important challenge to relate the
phenotype of a T cell population to its function, further
studies have to address functional aspects such as
response  in vitro to chemotactic gradients, cytokine
release and cytotoxic activity of distinct T cell populations.
Detection of the inducible inflammatory chemokine recep-
tors CCR5 and CCR3 on CD45RA+ T cells suggests that
CD45RA+ ‘revertants’ [9,20] might also constitute part of
the expanded population of memory T cells bearing
chemokine receptors in WG. A lack of CD27 expression
has been reported to distinguish effector cells from naive
T cells within the CD8+CD45RA+ T cell population [21].
However, Wills et al. [22] demonstrated that
cytomegalovirus-specific T cells, that is, antigen-experi-
enced T cells, are found within the fractions of
CD27+CD28– and CD27–CD28– T cells. These cells
either express CD45RA or CD45RO. Cytomegalovirus-
specific T cells, that is, antigen-experienced T cells, are
mainly CD28– and can also express CCR5 [10,23,24].
The fraction of CD28– T cells is also expanded in WG and
is correlated with organ involvement [25–28]. These find-
ings support our designation of CD45RA+ T cells express-
ing the inducible inflammatory chemokine receptors
CCR5 and CCR3 as T cell ‘revertants’.
A fraction of memory T cells also expressed CD62L con-
tributing to the phenotypic heterogeneity of T cells in WG.
CD62L expression was significantly higher on
CD4+CD45RA+ and CD8+CD45RA+ T cells not express-
ing CCR5 or CCR3, which might represent naive T cells.
CD62L mediates the homing of naive T cells through inter-
action with glycoprotein ligands on high endothelial
venules in secondary lymphoid tissues. Memory T cells
were previously thought to have lost CD62L expression
completely. However, our results are in line with those of
two other studies also demonstrating CD62L expression
on part of the memory T cell population [12,29]. CD62L
expression might in fact be lost only some time after differ-
entiation into tissue-specific memory T cells [12,29]. Thus,
CD4+CD45RA+ and CD8+CD45RA+ T cells expressing
the inducible inflammatory chemokine receptors CCR5 or
CCR3 as well as CD62L might constitute part of the
CD45RA+ ‘revertant’ memory T cell fraction.
We have previously shown that cytokine production is
upregulated in patients with active disease and ineffective
therapy [30]. In the present study we analyzed two groups
of patients with generalized WG: patients with active
disease (failure of immunosuppression) and patients in
remission (responding to immunosuppressive therapy).
We found no significant differences in mean percentage
of CCR5 expression and CCR3 expression on the CD4+
and CD8+ memory T cell subsets between active general-
ized WG and generalized WG in remission. Popa et al.
[31] also found markers of T cell activation such as HLA-
DR to be upregulated during remission of generalized
WG. The overall level of chemokine receptor expression
was higher in patients with localized WG than in those
with generalized WG. Higher doses of corticosteroids
might have influenced the overall level of chemokine
receptor expression in generalized WG but do not explain
differences in the expression of CCR5 and CCR3
between localized and generalized WG.
Moreover, the overall level of chemokine receptor expres-
sion in generalized WG might have been influenced by a
depletion of CCR5+ and CCR3+ T cells owing to
enhanced recruitment into inflammatory sites. Downregu-
lation of the cell-surface expression of the inducible inflam-
matory chemokine receptors CCR5 and CCR3 during
longer phases of disease activity might be another mecha-
nism influencing the overall level of their expression in gen-
eralized WG [32]. As stated above, granulomatous lesions
of the respiratory tract express predominantly Th1-type
cytokines in localized WG [3]; a shift toward stronger Th2-
type cytokine expression is found in granulomatous
lesions of the respiratory tract in generalized WG [3,4].
CCR5+ T cells have been ascribed to the effector memory
population producing Th1-type cytokines and CCR3+ T
cells to the effector memory population producing Th2-
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expression on memory T cells might favor the recruitment
of Th1-type effector memory T cells into granulomatous
lesions of the respiratory tract, whereas in generalized
WG the CCR3-mediated recruitment of Th2-type effector
memory T cells might have a larger role. In kidney lesions
of generalized WG, Th1-type as well as Th2-type cytokine
expression and CCR5 and CCR3 expression have been
described in generalized WG [4,5]. Changes in the
cytokine balance might influence disease activity, as exem-
plified by a patient with localized WG whose disease
activity flared and generalization of WG occurred during
an acute hepatitis C virus infection and interferon-α
therapy [33].
The present study shows that not only ‘classical’
chemokine-receptor-bearing CD45RO+ T cells, but also
CD45RA+ ‘revertants’ within the CD4+ and CD8+ T cell
populations, contribute to the phenotypic heterogeneity of
memory T cells in WG. CD62L expression is also found
on some memory T cells. Differences in CCR5 and CCR3
expression on effector memory T cells might favor the
migration of distinct Th1-type and Th2-type T cell popula-
tions into granulomatous lesions and vasculitic areas,
resulting in differences in tissue cytokine patterns found in
localized WG and generalized WG.
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